History

2023

• The merger between ACQ Bure and Yubico was finalised. Bure acquired the holding in Yubico in an internal transaction from Bure Growth for SEK 971M. In the merger between ACQ Bure and Yubico, Bure received a merger consideration of 7,851,942 shares in ACQ Bure and SEK 564M. Bure acquired an additional 190,000 shares in ACQ Bure’s placement of shares and rights issue for SEK 19M. ACQ Bure was then renamed Yubico AB and listed on the First North. Bure’s holding in Yubico amounts to 15,041,943 shares, corresponding to 17.5 per cent of the total number of shares.
• Bure acquired shares in Cavotec's, Ovzon's and Xvivo's rights issues for SEK 58M, SEK 83M and SEK 35M, respectively.
• Atle paid an additional purchase price for Atle Investment Services and HealthInvest Partners of SEK 61M and made conditional shareholder contributions to Atle Investment Services and HealthInvest Partners totalling SEK 13M.
• Bure Growth invested SEK 36M in ScandiNova, SEK 62M in BioLamina and SEK 5M in My Driving Academy.
• Bure divested 3,7 million shares in Mycronic for SEK 870M for an exit gain of SEK 813M.

‍

2022

• Bure acquired 0.1 million shares in Mentice’s share issue for SEK 9M.
• Atle acquired shares in HealthInvest Partners, paid additional purchase costs for Atle Investment Services and Humle Fonder and submitted a conditional shareholder contribution to Atle Investment Management for a total of SEK 61M.
• My Driving Academy acquired Mårtenssons, creating Sweden’s largest driving school. Bure Growth acquired shares for SEK 13M in My Driving Academy’s share issue.
• Bure Growth acquired shares in ScandiNova Systems for SEK 2M.
• Bure divested Investment AB Bure to Sandahlsbolagen Sweden.
• Bure divested 0.8 million shares in Cavotec to David Pagels, Cavotec CEO, for SEK 11M.

‍

2021

• ACQ Bure, Sweden’s first SPAC, was listed on the Nasdaq Stockholm in March 2021. Bure invested SEK 700M as a sponsor.
• In December 2020, Bure announced a cash offer to shareholders of Allgon AB (publ.). In February 2021, Bure’s holding reached 93.2 per cent and Bure announced a compulsory redemption of outstanding shares. Bure’s holding amounts to 100 per cent with an investment of SEK 746M.
• Bure acquired shares in Vitrolife for SEK 351M.
• Bure acquired shares in Ovzon’s rights issue for SEK 32M.
• Bure acquired shares in Xvivo Perfusion’s rights issue for SEK 15M.
• Atle Investment Management completed the acquisition of Humle Fonder and assumed management of Humle Småbolagsfond and Humle Sverigefond.
• Bure Growth acquired shares in BioLamina for SEK 17M.
• Bure Growth divested the holding in Life Genomics for SEK 11M.
• Bure divested its holding in MedCap for SEK 597M.
• Bure divested shares in Mycronic for SEK 259M.

‍

2020

• Bure acquired 8.5 million shares in Cavotec for SEK 136.7 million and increased the shareholding to 36.2 per cent.
• Bure acquired 1.2 million shares in Mentice for SEK 51.7 million and increased the shareholding to 14.7 per cent.
• Bure subscribed its share corresponding to SEK 17.5 million in the Ovzon preferential rights issue.
• Bure subscribed for shares for SEK 32.3 million in the Xvivo NCB directed new issue.
• Bure Growth acquired 25,000 shares in Yubico for SEK 9.0 million.
• Bure Growth acquired shares in the BioLamina preferential rights issue for SEK 13.2 million and acquired shares for SEK 53.2 million and increased the shareholding to 44.8 per cent.
• Bure executed a directed new issue of SEK 1 billion to institutional investors.
• Bure published a cash offer to shareholders of Allgon AB (publ). During December 2020, Bure acquired 6.4 million shares in Allgon for SEK 70.9 million.

‍

2019

• Bure acquired additional shares in Cavotec for SEK 74M, and increased its holding to 27.1 per cent.
• Acquisition of shares in Mentice for SEK 120M in conjunction with the company’s stock market flotation, equivalent to a holding of 10.1 per cent.
• Bure acquired additional shares in Ovzon for SEK 113M, and increased its holding to 14.3 per cent.
• Acquisition of shares in ScandiNova Systems for SEK 81M, equivalent to a holding of 27.8 per cent.
• Bure acquired additional shares in Yubico for SEK 54M.
• Total divestment of shares in Mycronic for SEK 270M, which resulted in an exit gain of SEK 245M.
• Divestment of shares in Vitrolife for SEK 384M, which resulted in an exit gain of SEK 370M.

‍

2018

• Bure celebrated its 25th anniversary 1993 – 2018.
• Bure acquired an additional 4.2 million shares in Cavotec for SEK 104 million and increased the shareholding to 25.4 per cent.
• Bure acquired 12.0 per cent in Ovzon for SEK 71 million.
• Bure Growth acquired additional shares in Yubico for SEK 33 million. Bure Growth invested SEK 9 million in My Driving Academy and increased its ownership to 32.0 per cent.
• Bure Financial Services acquired 32.5 per cent in Alcur Fonder AB.
• Bure sold 0.6 million shares in Xvivo Perfusion for SEK 57 million, which resulted in an exit result of SEK 45 million.

2017

• Bure acquired an additional 2.8 million shares in Cavotec for SEK 72M, increasing its holding to 20.1 per cent.
• Bure acquired an additional 0.04 million shares in MedCap for SEK 1M, increasing its holding to 23.0 per cent.
• Bure Growth acquired 18.2 per cent of shares in the security company Yubico.
• Bure Growth acquired 22.5 per cent of My Driving Academy Sweden.
• Bure acquired an additional 0.15 million shares in BioLamina for SEK 11M, increasing its holding to 29.1 per cent.
• Bure divested 0.2 million shares in Vitrolife for SEK 100M, generating an exit gain of SEK 93M.
• Bure Financial Services divested all its shares in Catella for SEK 193M, generating an exit gain of SEK 138M.
• Bure Growth divested all its shares in Vigmed Holding for SEK 8M, generating an exit loss of SEK 28M.

2016

• Bure acquired 2.75 million shares in Cavotec for SEK 55.1M and increased its holding from 13.1 per cent to 16.6 per cent.
• Bure acquired 4.6 million shares in Lauritz.com for SEK 68.9M, which corresponds to a holding of 11.3 per cent.
• Bure acquired 0.4 million shares in MedCap for SEK 11.2M and increased its holding from 20.0 per cent to 22.7 per cent.
• Bure Growth acquired shares in Life Genomics AB, which offers genetic tests to the healthcare sector and the public. The investment amounted to SEK 7M and the holding is 28 per cent.

2015

• Bure acquired an additional 2.0 million shares in Cavotec for SEK 56.4M, after which the holding amounts to 13.1 per cent.
• Bure Financial Services acquired an additional 0.3 million shares in Catella for SEK 3.1M, after which the holding amounts to 10.8 per cent of the share capital and 11.1 per cent of the number of votes.
• Bure Growth is established as a holding company for the stakes in Vigmed Holding and BioLamina. Bure Growth increased its holding in BioLamina from 17.0 per cent to 21.8 per cent.
• Bure sold the holding in PartnerTech for SEK 189.1M to Scanfil Oyj, which made a public tender offer for the company. The purchase consideration received exceeded the value of the shares in PartnerTech by SEK 52.4M at 31 December 2014. The exit gain amounted to SEK 22.7M.
• Bure sold 7.8 million shares in Mycronic for SEK 499M, which resulted in an exit gain of SEK 394M. The holding thereafter amounts to 29.9 per cent.

2014

• Henrik Blomquist is appointed CEO by the Board of Directors (acting CEO since April 2013).
• Bure acquires 9.98 per cent of the shares in Catella AB (publ), listed on Nasdaq Stockholm.
• Bure acquires 10.0 per cent of the shares in Cavotec SA, listed on Nasdaq Stockholm.
• Bure acquires 20.1 per cent of the shares in Fondbolaget Fondita Ab in Finland.
• Bure Financial Services is established as the holding company for the shareholdings in Catella and Fondbolaget Fondita Ab.
• Bure divests 1 million shares in Vitrolife, 300,000 shares in Xvivo Perfusion and a smaller shareholding in PartherTech to the management of PartnerTech.

2013

• Patrik Tigerschiöld is elected as the new Chairman at the Annual General Meeting. Previous Vice President Henrik Blomquist is appointed acting CEO.
• As of the second quarter, MedCap is reported as a portfolio company.

2012

• Bure invests SEK 218m in locomotives for leasing to the train operator RushRail, which has signed a long-term transport agreement with Trätåg AB, a logistics company owned by Stora Enso and BillerudKorsnäs.
• The holdings in the Carnegie companies are divested, increasing Bure’s net cash by SEK 629m. The exit gain in the Parent Company, SEK 279m, provides an IRR of 26 per cent.
• Vitrolife distributed its transplantation business to the shareholders by forming Xvivo Perfusion. Bure receives 26.3 per cent of the new company, which is listed on NASDAQ OMX First North in October.

2011

• Emphasis on the financial sector with the three independent Carnegie companies, Carnegie Holding, Carnegie Asset Management and Max Matthiessen.
• Voluntary redemption procedure for approximately SEK 200m.
• The holdings in Aptilo, SRC, Chimney Pot and H. Lundén are divested.

2010

• Merger between Bure and Skanditek Industriförvaltning.
• Cash dividends of approximately SEK 500m.
• New CEO.
• Carnegie acquires HQ Bank and HQ Fonder.
• The holdings in Energo (IRR of 29 per cent) and AcadeMedia (IRR of 40 per cent) are divested.

2009

• Carnegie Investment Bank and Max Matthiessen are acquired from the Swedish National Debt Office.
• Carnegie Asset Management is separated from Carnegie Investment Bank.
• Voluntary redemption procedure for approximately SEK 1bn.

2008

• Skanditek Industriförvaltning is the largest shareholder in AcadeMedia.
• The holding in the new group AcadeMedia is distributed to Bure’s shareholders.
• Merger between Anew Learning and AcadeMedia.
• The holdings in Textilia and Citat are divested.

2007

• Capital distribution to the shareholders of nearly SEK 1.5bn through share buybacks, warrants and redemption procedure.
• The educational operations are coordinated in the group Anew Learning.
• Bure acquires holding in AcadeMedia.

2006

• Bure acquires the independent schools IT-Gymnasiet and Framtidsgymnasiet.
• The holdings SysTeam, Cygate and Carl Bro are divested.
• Energo is acquired and a market-leading engineering consultancy is established together with Bure’s subsidiary Retea.
• Citat acquires Appelberg.

2005

• The holding in Mölnlycke Health Care is divested.
• Ownership in Vittra is increased.

2004

• Skanditek Industriförvaltning becomes Bure’s largest shareholder.
• The holdings in Parere, Informator, Elmo Leather, XDIN and Stark Film och Event are divested.

2003

• Bure undergoes a financial crisis, carries out new share issue for SEK 800m.

2000

• The Health Care business area is listed under the name Capio AB and distributed to the shareholders.
• The holding in Observer is distributed to the shareholders.
• Carl Bro and Appelberg Publishing Agency are acquired.

1998

• The Education business are is established.
• S:t Göran’s Hospital is acquired.
• The holding in Sifo Group is increased through the acquisition of Romeike.

1996

• The IT/InfoMedia business area is established.
• Acquisition of Guide Datakonsult, Previa, Länia Material and Mälardiagnostik, among others.

1993

• The share is listed on the Stockholm Stock Exchange.
• The Health Care business area is established.

1992

• Bure is formed from the phase-out of the Swedish wage-earners’ investment funds.